Lanreotide Acetate, CAS No.: 118992-92-0 CAS NO.108736-35-2
- FOB Price: USD: 15.00-15.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: T/T,Other
- Available Specifications:
pharmaceutical grade(1-1000)Gram
- Product Details
Keywords
- Peptides
- Pharmaceutical Intermediate
- Chemical
Quick Details
- ProName: Lanreotide Acetate, CAS No.: 118992-92...
- CasNo: 108736-35-2
- Molecular Formula: C54H69N11O10S2
- Appearance: White Powder
- Application: bodybuilding pharmaceutical material, ...
- DeliveryTime: 3days
- PackAge: Packaging can be according to customer
- Port: Shanghai
- ProductionCapacity: 10000 Metric Ton/Day
- Purity: 99%
- Storage: Keep it under seal in cool and dark pl...
- Transportation: FEDEX DHL TNT UPS EUB
- LimitNum: 1 Gram
- Related Substances: Peptides
- Residue on Ignition: 0
- Heavy Metal: 0
- Valid Period: 2years
- CasNo: 108736-35-2
- Molecular Formula: C54H69N11O10S2
- Appearance: detailed see specifications
- Purity: 99%
- Grade: Grade
- LimitNum: 1 Gram
Superiority
This is Allen from Zhengzhou Filter Biotechnology Co.,Ltd.We are the professional supplier of peptide products in China over 10 years. we have Professional Lab to confirm the Quality and Serive for all clients in long-term run cooperation.
Our Company as a Pharmaceutical Raw Material Manufacturer specialize in R&D the New Drugs and Producing the Generic Medicine:
Amino Acids&Vitamins
Pharmaceutical Polypeptide,
Comestic Polypeptide,
Veterinary Peptide and
Pharmaceutical APIs.
Due to of the high quality and good service, They have been exported more than 30 countries.
Sincerely hope to have a chance to cooperate with you
Details
Description
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,a rare tumor of the pituitary gland which secretes TSH.
Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.